Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Sells $2,602,110.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens sold 21,000 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now directly owns 43,337 shares of the company’s stock, valued at $5,369,887.67. This trade represents a 32.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mesa Laboratories Price Performance

NASDAQ:MLAB opened at $121.89 on Thursday. The business’s 50-day moving average is $137.47 and its 200 day moving average is $129.24. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $155.12. The company has a market capitalization of $662.35 million, a P/E ratio of -2.63 and a beta of 0.82. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, February 28th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend was Friday, February 28th. Mesa Laboratories’s payout ratio is -1.38%.

Hedge Funds Weigh In On Mesa Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. lifted its holdings in shares of Mesa Laboratories by 4.3% in the 4th quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier’s stock valued at $231,000 after acquiring an additional 73 shares during the last quarter. Berry Wealth Group LP raised its position in Mesa Laboratories by 5.3% during the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock valued at $219,000 after purchasing an additional 83 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Mesa Laboratories by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 98 shares during the period. FMR LLC lifted its stake in shares of Mesa Laboratories by 34.1% in the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 100 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in shares of Mesa Laboratories by 3.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier’s stock worth $448,000 after purchasing an additional 100 shares during the period. 90.60% of the stock is owned by hedge funds and other institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.